Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Massachusetts Institute of Technology | 38 |
| 2 | Ascendis Pharma AS | 29 |
| 3 | Harvard University | 28 |
| 4 | State University System of Florida | 14 |
| 5 | Imperial Brands PLC | 13 |
| 6 | Virginia Polytechnic Institute and State University | 10 |
| 7 | Regeneron Pharmaceuticals Inc | 9 |
| 8 | Toray Industries Inc | 6 |
| 9 | Biomarin Pharmaceutical Inc | 3 |
| 10 | Dow Inc | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 244 |
| 2 | A61P | Therapeutic activity (drug indications) | 153 |
| 3 | C07K | Peptides | 140 |
| 4 | C12N | Microorganisms, enzymes | 112 |
| 5 | Y02A | Climate change adaptation | 30 |
| 6 | C12Y | Enzyme nomenclature (EC numbers) | 29 |
| 7 | C08J | Working-up of plastics | 18 |
| 8 | A61M | Devices for introducing media into the body | 16 |
| 9 | C12Q | Measuring/testing involving enzymes | 15 |
| 10 | A24F | 14 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| USE OF PEPTIDE Thr-Lys-Pro-Arg-Pro-Gly-Pro (SELANC) HEPATOPROTECTIVE FOR EXPOSURE IN ACUTE IMMOBILISATION STRESS | 2016 | 4 | |
| APPLICATION OF Thr-Lys-Pro-Arg-Pro-Gly-Pro PEPTIDE (SELANK) FOR TOXIC HEPATITIS PREVENTION AND TREATMENT | 2017 | 3 | |
| USE OF THE PEPTIDE Thr-Lys-Pro-Arg-Pro-Gly-Pro (SELANK) TO INCREASE BODY RESISTANCE TO ACUTE HYPOTHERMIA | 2019 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 3 |
| 2017 | 6 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | N. F. Myasoedov | Institute of Molecular Genetics | 19 |
| 2 | Л. А. Андреева | Institute of Molecular Genetics | 18 |
| 3 | Н. В. Кост | Mental Health Research Center of Russian Academy of Medical Sciences | 12 |
| 4 | O. Yu. Sokolov | Mental Health Research Center of Russian Academy of Medical Sciences | 12 |
| 5 | И. И. Козловский | Institute of Pharmacology Russian Academy of Medical Sciences | 10 |
| 6 | М. И. Шадрина | Institute of Molecular Genetics | 8 |
| 7 | Timur Kolomin | Institute of Molecular Genetics | 8 |
| 8 | Yu. A. Zolotarev | Institute of Molecular Genetics | 7 |
| 9 | P. A. Slominsky | Institute of Molecular Genetics | 6 |
| 10 | Kozlovskaia Mm | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Sedative‐Hypnotic Agents That Impact Gamma‐Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma‐Hydroxybutyric Acid, Phenibut, and Selank | 2021 | 25 | Neurotransmitter Receptor Influence on Behavior |
| Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission | 2016 | 19 | Neuroscience and Neuropharmacology Research |
| Selank and Short Peptides of the Tuftsin Family in the Regulation of Adaptive Behavior in Stress | 2003 | 19 | Neurotransmitter Receptor Influence on Behavior |
| The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity | 2001 | 15 | Stress Responses and Cortisol |
| Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential for their practical application | 2006 | 13 | Receptor Mechanisms and Signaling |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Selank?
Which institutions hold the most patents related to Selank?
What research trends are evident in Selank-related publications and patents?
What are the primary research areas associated with Selank according to patent classifications?
Who are the leading authors in Selank research?